209.39
-5.35 (-2.49%)
Penutupan Terdahulu | 214.74 |
Buka | 220.45 |
Jumlah Dagangan | 1,110,886 |
Purata Dagangan (3B) | 1,228,516 |
Modal Pasaran | 34,066,915,328 |
Harga / Pendapatan (P/E TTM) | 48.58 |
Harga / Pendapatan (P/E Ke hadapan) | 31.85 |
Harga / Jualan (P/S) | 14.02 |
Harga / Buku (P/B) | 6.51 |
Julat 52 Minggu | |
Tarikh Pendapatan | 28 May 2025 - 2 Jun 2025 |
Margin Keuntungan | 26.00% |
Margin Operasi (TTM) | 26.14% |
EPS Cair (TTM) | 4.31 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 14.30% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 32.70% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.30% |
Nisbah Semasa (MRQ) | 4.51 |
Aliran Tunai Operasi (OCF TTM) | 1.09 B |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 942.78 M |
Pulangan Atas Aset (ROA TTM) | 6.57% |
Pulangan Atas Ekuiti (ROE TTM) | 13.63% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Health Information Services (US) | Menurun | Bercampur |
Health Information Services (Global) | Menurun | Bercampur | |
Stok | Veeva Systems Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 1.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 0.5 |
Purata | 0.75 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company. |
|
Sektor | Healthcare |
Industri | Health Information Services |
Gaya Pelaburan | Mid Growth |
% Dimiliki oleh Orang Dalam | 8.58% |
% Dimiliki oleh Institusi | 86.68% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 285.00 (Baird, 36.11%) | Beli |
Median | 250.00 (19.39%) | |
Rendah | 201.00 (Morgan Stanley, -4.01%) | Jual |
Purata | 250.22 (19.50%) | |
Jumlah | 5 Beli, 3 Pegang, 1 Jual | |
Harga Purata @ Panggilan | 232.65 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Piper Sandler | 23 Apr 2025 | 255.00 (21.78%) | Beli | 220.53 |
Keybanc | 16 Apr 2025 | 250.00 (19.39%) | Beli | 220.66 |
JP Morgan | 20 Mar 2025 | 249.00 (18.92%) | Pegang | 235.85 |
Baird | 06 Mar 2025 | 285.00 (36.11%) | Beli | 236.14 |
Morgan Stanley | 06 Mar 2025 | 201.00 (-4.01%) | Jual | 236.14 |
Needham | 06 Mar 2025 | 270.00 (28.95%) | Beli | 236.14 |
Scotiabank | 06 Mar 2025 | 245.00 (17.01%) | Pegang | 236.14 |
Stephens & Co. | 06 Mar 2025 | 280.00 (33.72%) | Beli | 236.14 |
Truist Securities | 06 Mar 2025 | 217.00 (3.63%) | Pegang | 236.14 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
20 May 2025 | Pengumuman | More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality |
07 May 2025 | Pengumuman | Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 |
06 May 2025 | Pengumuman | Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit |
29 Apr 2025 | Pengumuman | Announcing Veeva AI |
01 Apr 2025 | Pengumuman | Veeva Announces Research Site Clinical Trial Management System |
19 Mar 2025 | Pengumuman | Indero Marks 40th Study Live with Veeva RTSM |
11 Mar 2025 | Pengumuman | Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' |
05 Mar 2025 | Pengumuman | Veeva Announces Fourth Quarter and Fiscal Year 2025 Results |
04 Mar 2025 | Pengumuman | Veeva Commercial Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries |
03 Mar 2025 | Pengumuman | Top Global Biopharmas Standardize on Veeva China CRM Suite |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |